Peptide blend · Research Monograph · Three-peptide research blend: BPC-157 + TB-500 + GHK-Cu

Glow

Three-peptide blend · dermal and matrix models

Also known as GLOW Protocol · GHK-Cu + BPC-157 + TB-500

Glow is a blend. Several peptides are combined and freeze-dried into a single 70 mg vial, chosen from compounds studied in skin and connective tissue models. Research on the individual ingredients covers collagen production, tissue structure, and how skin cells move and multiply. It is supplied for researchers testing several pathways together rather than one at a time.

Size
70mg
Form
Lyophilized Powder
View product & pricing → Lot records & COAs

For laboratory research use only - not for human or animal use

Glow vial from the Eon Peptides research catalog
Glow · 70mg · catalog photograph
Available in the Eon catalog - Glow from $105.00 View certificate of analysisAccurate Test Labs · 99.84% purity · Lot GL-090226-70

Molecular data

Physical formLyophilized Powder
Available sizes70mg

How it works

  1. BPC-157

    VEGF Pathway

    Vessel formation, tissue granulation and nitric oxide signalling have been measured as endpoints in preclinical models.

    • Vessel formation measured
    • Tissue granulation scored
    • Modulates nitric oxide signaling
  2. TB-500

    Actin Regulation

    Cell migration, cytoskeletal remodelling and fibrotic scarring are measured via the thymosin beta-4 pathway.

    • Cell migration measured
    • Cytoskeletal remodelling observed
    • Fibrotic scarring scored
  3. GHK-Cu

    Collagen & ECM Remodeling

    Type I and III collagen synthesis measured, expression changes reported across 4,000+ genes, and copper delivered to tissue during extracellular matrix turnover.

    • Type I & III collagen measured
    • Modulates 4,000+ genes
    • Delivers copper to tissue

What the research shows

  1. Dermal

    Dermal Models

    GHK-Cu is studied for collagen synthesis; BPC-157 and TB-500 in epithelial and scarring models.

  2. Mechanistic

    Cytoskeletal & Vascular

    TB-500 is characterised for actin remodelling; tendon fibroblast viability is measured for BPC-157; vascularisation endpoints for GHK-Cu.

  3. Matrix

    Anti-Inflammatory

    All three peptides demonstrate anti-inflammatory properties through different mechanisms in animal models.

  4. Structural

    ECM Remodeling

    Extracellular matrix deposition and fibrotic scoring as combined endpoints.

Specification

ComponentsBPC-157 + TB-500 + GHK-Cu
Strength70mg
FormLyophilized powder
Purity≥99% (HPLC verified per component)
TestingThird-party HPLC, Mass Spec, Endotoxin
Storage-20°C for long-term stability
Light sensitivityProtect from direct light at all times
SolubilityWater-soluble
COAIncluded with every order
AppearanceWhite to off-white powder
Stability24 months from manufacture date when stored properly

How it's tested

Every lot of Glow released to the catalog carries a third-party certificate of analysis. 6 documented lots are on file for this compound, with reported HPLC purity from 99.54% to 99.91% (mean 99.72%), issued by Accurate Test Labs and Freedom Diagnostics. 3 of 6 certificates record identity as confirmed.

Documented lots
6
Reported purity
99.54% to 99.91%
Mean purity
99.72%
Issuing labs
Accurate Test Labs, Freedom Diagnostics

All certificates in the COA library →

Frequently asked questions

What is GLOW and what does it contain?

GLOW is a research peptide blend containing three peptides: BPC-157 (Body Protection Compound), TB-500 (Thymosin Beta-4), and GHK-Cu (copper peptide). Each is characterised on a different pathway - vascular, cell migration, and collagen synthesis respectively.

How do the three peptides work together?

In preclinical research, vessel formation (angiogenesis) is measured for BPC-157, cell migration via actin regulation for TB-500, and collagen production plus expression changes across 4,000+ genes for GHK-Cu. The three cover distinct pathways, which is the rationale for combining them.

Is GLOW FDA approved?

No. GLOW is not approved by the FDA for any medical use. It is sold exclusively for in vitro laboratory research purposes. The individual components have varying levels of preclinical evidence but no completed human clinical trials for the combined blend.

How should GLOW be stored?

Store lyophilized (powder) form at -20°C for maximum stability. Protect from direct light at all times and avoid repeated freeze-thaw cycles.

What purity testing is performed?

Each component undergoes independent third-party testing including HPLC (High Performance Liquid Chromatography) for purity verification, mass spectrometry for molecular weight confirmation, and endotoxin testing. Certificates of Analysis are included with every order.

What is the research evidence for this blend?

The rationale is based on individual component research in preclinical models. The combined blend has not been characterised as a single formulation. Complementarity is inferred from mechanism.

Selected preclinical literature

9 published studies on the components of Glow, limited by rule to animal models and cell-based (in vitro) work indexed in PubMed. Human trials, case reports and literature overviews are excluded. Glow is a blend, so papers are listed per component. Titles appear as published and each links to its PubMed record; the list was resolved against PubMed on 2026-10-12. A listing describes what a study examined, not a property of the material supplied.

  1. GHK-Cu · C. elegans model and in vitro

    The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways

    Biogerontology, 2026. PubMed PMID 42084774 · doi:10.1007/s10522-026-10444-x

  2. GHK-Cu · Mice model

    Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways

    Life sciences, 2020. PubMed PMID 31809714 · doi:10.1016/j.lfs.2019.117139

  3. GHK-Cu · Rats model

    Hydrogels based on low-methoxyl amidated citrus pectin and flaxseed gum formulated with tripeptide glycyl-l-histidyl-l-lysine improve the healing of experimental cutting wounds in rats

    International journal of biological macromolecules, 2020. PubMed PMID 33031852 · doi:10.1016/j.ijbiomac.2020.09.251

  4. BPC-157 · Rats model

    Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury

    Scientific reports, 2026. PubMed PMID 42204242 · doi:10.1038/s41598-026-55449-1

  5. BPC-157 · Rats model

    Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

    Joint diseases and related surgery, 2026. PubMed PMID 42542926 · doi:10.52312/jdrs.2026.2951

  6. BPC-157 · Rats model

    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint

    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2024. PubMed PMID 38583442 · doi:10.26402/jpp.2024.1.09

  7. TB-500 · Mice model and in vitro

    Decidualization-empowered ECM hydrogel integrating sustained Tβ4 release drives endometrial regeneration in intrauterine adhesions

    Nature communications, 2026. PubMed PMID 41565687 · doi:10.1038/s41467-026-68677-w

  8. TB-500 · Mice model and in vitro

    Plasmacytoid dendritic cells alleviate allergic asthma via airway epithelial cell-dependent thymosin β4 expression

    The Journal of allergy and clinical immunology, 2025. PubMed PMID 39978686 · doi:10.1016/j.jaci.2025.01.047

  9. TB-500 · Rats model

    Tβ4-Engineered ADSC Extracellular Vesicles Rescue Cell Senescence Through Separable Microneedle Patches for Diabetic Wound Healing

    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. PubMed PMID 40279568 · doi:10.1002/advs.202505009

Full preclinical study index for Glow →

  • GHK-CuCollagen Synthesis Studies
  • BPC-157Pentadecapeptide · Preclinical Models
  • TB-500Cell Migration Studies
  • KLOWFour-peptide blend · 80 mg lyophilized

For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.